Study Title | A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma |
---|---|
Protocol ID | MK-3475-051 |
Disease (Sub Disease) | Solid Tumour Lymphoma |
Diagnosis Stage | Relapse/ refractory |
Location | NSW / QLD / VIC |
Sponsor | Merck Sharp & Dohme Corp. |
Links | https://clinicaltrials.gov/ct2/show/NCT02332668 |
Trial Status | Open |
Trial Open Date | 04/04/2016 |
Sites | The Children's Hospital at Westmead / Queensland Children's Hospital/ Royal Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 6 months to 17 years |
International registry ID's | NCT02332668 |